Initial experience with oral valganciclovir for pre-emptive cytomegalovirus therapy after lung transplantation

被引:5
作者
Aigner, C [1 ]
Jaksch, P [1 ]
Winkler, G [1 ]
Czebe, K [1 ]
Taghavi, S [1 ]
Marta, G [1 ]
Klepetko, W [1 ]
机构
[1] Vienna Med Univ, Vienna Gen Hosp, Dept Cardiothorac Surg, A-1090 Vienna, Austria
关键词
lung transplantation; cytomegalovirus; CMV; pre-emptive therapy; valganciclovir;
D O I
10.1007/s00508-005-0413-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The most common opportunistic viral pathogen after lung transplantation is cytomegalovirus (CMV). Oral valganciclovir, a prodrug of ganciclovir, has been introduced as a potential drug for prophylaxis and treatment of CMV infection and disease in lung transplantation. The goal of this study was to describe our initial experience with oral valganciclovir for pre-emptive treatment of CMV infections after lung transplantation. Methods and patients: We summarize our experience with 19 patients who underwent lung transplantation and received pre-emptive oral valganciclovir therapy in the situation of positive CMV polymerase chain reaction (PCR) in either plasma or bronchoalveolar lavage. None of the patients presented with manifest CMV disease. Treatment dosage of valganciclovir was 450 mg to 1800 mg daily, depending on renal function and white blood count. Treatment was continued until the CMV PCR became negative, in any case for a period of at least 14 days. Results: Three patients received two courses of pre-emptive oral valganciclovir; 16 patients were treated once. Eleven patients (57.9%) were treated because of a positive plasma CMV PCR; in eight patients (42.1%) the PCR was positive only in bronchoalveolar lavage. Therapy was initiated 896 +/- 1186 days (range 108-3911) after transplantation with a mean CMV PCR of 45,536 +/- 149,294 copies (range 426-706,000). In all cases the PCR fell below detectability (< 400 copies) after a period of 22 +/- 10 days of treatment (range 7-50 days). Mild to moderate leucopenia was observed in seven patients (36.8%) during treatment. None of the patients developed new onset of other potentially drug-related disorders such as neutropenia, anemia, deterioration of renal function or gastrointestinal disorder. Conclusions: Pre-emptive therapy with oral valganciclovir for CMV infections detected by PCR in either plasma or bronchoalveolar lavage after lung transplantation seems to be efficacious and safe. However, regular blood counts should be performed to detect developing leucopenia.
引用
收藏
页码:480 / 484
页数:5
相关论文
共 17 条
[1]   Is it possible to reduce CMV-infections after heart transplantation with a three-month antiviral prophylaxis?: 7 years experience with Ganciclovir [J].
Antretter, H ;
Höfer, D ;
Hangler, H ;
Larcher, C ;
Pölzl, G ;
Hörmann, C ;
Margreiter, J ;
Margreiter, R ;
Laufer, G ;
Bonatti, H .
WIENER KLINISCHE WOCHENSCHRIFT, 2004, 116 (15-16) :542-551
[2]   LUNGS ARE A MAJOR ORGAN SITE OF CYTOMEGALOVIRUS LATENCY AND RECURRENCE [J].
BALTHESEN, M ;
MESSERLE, M ;
REDDEHASE, MJ .
JOURNAL OF VIROLOGY, 1993, 67 (09) :5360-5366
[3]   Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients [J].
Bhorade, SM ;
Lurain, NS ;
Jordan, A ;
Leischner, J ;
Villanueva, J ;
Durazo, R ;
Creech, S ;
Vigneswaran, WT ;
Garrity, ER .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2002, 21 (12) :1274-1282
[4]   Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients [J].
Boivin, G ;
Goyette, N ;
Gilbert, C ;
Roberts, N ;
Macey, K ;
Paya, C ;
Pescovitz, MD ;
Humar, A ;
Dominguez, E ;
Washburn, K ;
Blumberg, E ;
Alexander, B ;
Freeman, R ;
Heaton, N ;
Covington, E .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (09) :1615-1618
[5]   Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation [J].
Ciancio, G ;
Burke, GW ;
Mattiazzi, A ;
Leibovici, Z ;
Dowdy, L ;
Roth, D ;
Kupin, W ;
Rosen, A ;
Jorge, D ;
Cirocco, RE ;
Miller, J .
CLINICAL TRANSPLANTATION, 2004, 18 (04) :402-406
[6]   Pharmacokinetics of valganciclovir and ganciclovir in renal impairment [J].
Czock, D ;
Scholle, C ;
Rasche, FM ;
Schaarschmidt, D ;
Keller, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (02) :142-150
[7]   Preemptive treatment for the prevention of cytomegalovirus disease - In lung and heart transplant recipients [J].
Egan, JJ ;
Lomax, J ;
Barber, L ;
Lok, SS ;
Martyszczuk, R ;
Yonan, N ;
Fox, A ;
Deiraniya, AK ;
Turner, AJ ;
Woodcock, AA .
TRANSPLANTATION, 1998, 65 (05) :747-752
[8]   Infection in organ-transplant recipients [J].
Fishman, JA ;
Rubin, RH .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (24) :1741-1751
[9]  
Gotzinger P, 1996, WIEN KLIN WOCHENSCHR, V108, P795
[10]   Therapeutic developments in cytomegalovirus retinitis [J].
Hoffman, VF ;
Skiest, DJ .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (02) :207-220